Universidad de Castilla-La Mancha Departamento de Ciencias Médicas, Albacete, Spain.
The aim of this work was to study if a G1-polyamidoamine dendrimer/siRNA dendriplex can remove the p42 MAPK protein in prostate cancer cells and to potentiate the antitumoral effect of the antidiabetic drug metformin and taxane docetaxel.
The dendriplex uptake was studied using flow cytometry analysis. Transfection efficiency was determined by measuring p42 MAPK mRNA and protein levels. Antitumoral effects were determined by measuring cellular proliferation and damage.
The dendriplex siRNA/G1-polyamidoamine dendrimer decreased both p42 MAPK mRNA and protein levels by more than 80%, which potentiates the antitumoral effects of metformin.
Blockade of the MAPK pathway using a dendrimer-vehiculized siRNA to block the MAPK signaling pathway in prostate cancer cells can potentiate the antitumoral activity of anticancer drugs, indicating that the combination of siRNA-mediated blockade of survival signals plus antitumoral therapy might be a useful approach for cancer therapy.
Written by:
Monteagudo S, Pérez-Martínez FC, Pérez-Carrión MD, Guerra J, Merino S, Sánchez-Verdú MP, Ceña V. Are you the author?
Reference: Nanomedicine (Lond). 2011 Oct 13. Epub ahead of print.
doi: 10.2217/nnm.11.61
PubMed Abstract
PMID: 21995500
UroToday.com Investigational Urology Section
